The Low-density lipoproteins (LDL) as well as all the ApoB-containing lipoproteins (VLDL remnants and Lp(a)) are etiological factors of atherosclerotic cardiovascular diseases (ASCVD). Several published consensuses [1–3] have reached this conclusion based on the evidence of experimental, observational, and randomized controlled interventional studies. Overall randomized controlled trials (RCTs) and Mendelian randomization studies have determined that a reduction of 1 mmol/L of LDL-C results in a short term (5 years) 22% reduction and in a lifetime reduction of 50% of the relative risk of ASCVD.
